Cargando…

Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection

Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanner, Rachel, Satti, Iman, Harris, Stephanie A., O'Shea, Matthew K., Cizmeci, Deniz, O'Connor, Daniel, Chomka, Agnieszka, Matsumiya, Magali, Wittenberg, Rachel, Minassian, Angela M., Meyer, Joel, Fletcher, Helen A., McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968127/
https://www.ncbi.nlm.nih.gov/pubmed/31998295
http://dx.doi.org/10.3389/fimmu.2019.02983
_version_ 1783489077439365120
author Tanner, Rachel
Satti, Iman
Harris, Stephanie A.
O'Shea, Matthew K.
Cizmeci, Deniz
O'Connor, Daniel
Chomka, Agnieszka
Matsumiya, Magali
Wittenberg, Rachel
Minassian, Angela M.
Meyer, Joel
Fletcher, Helen A.
McShane, Helen
author_facet Tanner, Rachel
Satti, Iman
Harris, Stephanie A.
O'Shea, Matthew K.
Cizmeci, Deniz
O'Connor, Daniel
Chomka, Agnieszka
Matsumiya, Magali
Wittenberg, Rachel
Minassian, Angela M.
Meyer, Joel
Fletcher, Helen A.
McShane, Helen
author_sort Tanner, Rachel
collection PubMed
description Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays (MGIAs) provide an unbiased measure of ability to control mycobacterial growth in vitro, and may represent a functional correlate of protection. However, the biological relevance of any potential correlate can only be assessed by determining the association with in vivo protection from either a controlled mycobacterial infection or natural development of TB disease. Our data demonstrate that the direct MGIA using peripheral blood mononuclear cells (PBMC) is measuring a biologically relevant response that correlates with protection from in vivo human BCG infection across two independent cohorts. This is the first report of an MGIA correlating with in vivo protection in the species-of-interest, humans, and furthermore on a per-individual as well as per-group basis. Control of mycobacterial growth in the MGIA is associated with a range of immune parameters measured post-BCG infection in vivo including the IFN-γ ELISpot response, frequency of PPD-specific IFN-γ or TNF-α producing CD4+ T cells and frequency of specific sub-populations of polyfunctional CD4+ T cells. Distinct transcriptomic profiles are associated with good vs. poor mycobacterial control in the MGIA, with good controllers showing enrichment for gene sets associated with antigen processing/presentation and the IL-23 pathway, and poor controllers showing enrichment for hypoxia-related pathways. This study represents an important step toward biologically validating the direct PBMC MGIA for use in TB vaccine development and furthermore demonstrates the utility of this assay in determining relevant immune mechanisms and pathways of protection.
format Online
Article
Text
id pubmed-6968127
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69681272020-01-29 Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection Tanner, Rachel Satti, Iman Harris, Stephanie A. O'Shea, Matthew K. Cizmeci, Deniz O'Connor, Daniel Chomka, Agnieszka Matsumiya, Magali Wittenberg, Rachel Minassian, Angela M. Meyer, Joel Fletcher, Helen A. McShane, Helen Front Immunol Immunology Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays (MGIAs) provide an unbiased measure of ability to control mycobacterial growth in vitro, and may represent a functional correlate of protection. However, the biological relevance of any potential correlate can only be assessed by determining the association with in vivo protection from either a controlled mycobacterial infection or natural development of TB disease. Our data demonstrate that the direct MGIA using peripheral blood mononuclear cells (PBMC) is measuring a biologically relevant response that correlates with protection from in vivo human BCG infection across two independent cohorts. This is the first report of an MGIA correlating with in vivo protection in the species-of-interest, humans, and furthermore on a per-individual as well as per-group basis. Control of mycobacterial growth in the MGIA is associated with a range of immune parameters measured post-BCG infection in vivo including the IFN-γ ELISpot response, frequency of PPD-specific IFN-γ or TNF-α producing CD4+ T cells and frequency of specific sub-populations of polyfunctional CD4+ T cells. Distinct transcriptomic profiles are associated with good vs. poor mycobacterial control in the MGIA, with good controllers showing enrichment for gene sets associated with antigen processing/presentation and the IL-23 pathway, and poor controllers showing enrichment for hypoxia-related pathways. This study represents an important step toward biologically validating the direct PBMC MGIA for use in TB vaccine development and furthermore demonstrates the utility of this assay in determining relevant immune mechanisms and pathways of protection. Frontiers Media S.A. 2020-01-10 /pmc/articles/PMC6968127/ /pubmed/31998295 http://dx.doi.org/10.3389/fimmu.2019.02983 Text en Copyright © 2020 Tanner, Satti, Harris, O'Shea, Cizmeci, O'Connor, Chomka, Matsumiya, Wittenberg, Minassian, Meyer, Fletcher and McShane. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tanner, Rachel
Satti, Iman
Harris, Stephanie A.
O'Shea, Matthew K.
Cizmeci, Deniz
O'Connor, Daniel
Chomka, Agnieszka
Matsumiya, Magali
Wittenberg, Rachel
Minassian, Angela M.
Meyer, Joel
Fletcher, Helen A.
McShane, Helen
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
title Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
title_full Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
title_fullStr Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
title_full_unstemmed Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
title_short Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
title_sort tools for assessing the protective efficacy of tb vaccines in humans: in vitro mycobacterial growth inhibition predicts outcome of in vivo mycobacterial infection
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968127/
https://www.ncbi.nlm.nih.gov/pubmed/31998295
http://dx.doi.org/10.3389/fimmu.2019.02983
work_keys_str_mv AT tannerrachel toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT sattiiman toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT harrisstephaniea toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT osheamatthewk toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT cizmecideniz toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT oconnordaniel toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT chomkaagnieszka toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT matsumiyamagali toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT wittenbergrachel toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT minassianangelam toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT meyerjoel toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT fletcherhelena toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection
AT mcshanehelen toolsforassessingtheprotectiveefficacyoftbvaccinesinhumansinvitromycobacterialgrowthinhibitionpredictsoutcomeofinvivomycobacterialinfection